Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Liang
NCT04421495: Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China	Active, not recruiting	4	608	RoW	Delamanid, anti-TB new drug containing regimen	Beijing Chest Hospital	Multidrug Resistant Tuberculosis	06/22	07/24
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2	Recruiting	3	366	RoW	RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda	RemeGen Co., Ltd.	Breast Cancer	06/24	12/24
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Recruiting	3	270	RoW	GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant	Genor Biopharma Co., Ltd.	Locally Advanced or Metastatic Breast Cancer	10/23	01/24
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer	Recruiting	3	350	RoW	GB491 combined with Letrozole, Placebo combined with Letrozole	Genor Biopharma Co., Ltd.	Breast Cancer	01/26	01/27
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer	Withdrawn	2	177	RoW	Balstilimab, Balstilimab + Zalifrelimab	Agenus Inc., Betta Pharmaceuticals Co., Ltd.	Cervical Cancer	12/24	12/24